CAMBRIDGE, Mass., Feb. 28 10, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the United States Patent and Trademark Office (USPTO) has issued another decision in favor of the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9 editing in human cells. Pending an appeal in the Federal Circuit, this decision ends U.S. patent interference between the University of California, University of Vienna and Emmanuelle Charpentier (collectively, CVC) and Broad.
This action by the USPTO is the second favorable ruling establishing Broad as the first group to invent the use of CRISPR/Cas9 to edit DNA in cells needed to manufacture gene-editing drugs for humans. With this decision, the USPTO has clearly determined that CVC was not the first to invent the use of CRISPR/Cas9 in eukaryotic cells, including human cells, and that CVC is not entitled to claims of patent on this subject. The patents at issue in the current interference belong to Broad and are exclusively licensed to Editas Medicine for the development of drugs for people with serious illnesses.
“While scientists from both groups have made important scientific contributions to the field, this procedure aimed to determine who invented the use of CRISPR/Cas9 to edit DNA in eukaryotic cells, including human cells. We are pleased with the U.S. Patent and Trademark Office’s decision ending the interference and determining the Broad Institute’s innovative work to discover and use CRISPR/Cas9 technology in human cells,” said James C. Mullen, Chief Executive Officer, Officer, Editas Medicine “This decision reaffirms the strength of our core intellectual property as we continue our work developing life-changing medicines for people with serious illnesses. We use this breakthrough technology to develop drugs, including our flagship EDIT-101 program for the treatment of ACL10.”
Editas Medicine’s core intellectual property includes issued patents covering fundamental aspects of CRISPR/Cas9 and CRISPR/Cas12a gene editing. Editas Medicine’s patents broadly cover CRISPR/Cas9 and CRISPR/Cas12a gene editing in all human cells. Successfully modifying this cell type is critical to making CRISPR-based drugs. Overall, the Company holds a wide range of fundamental intellectual property covering all components of its genome editing platform as well as enabling and product-specific intellectual property. Patents covering the use of CRISPR/Cas9 and CRISPR/Cas12a for gene editing of human cells have been granted in the United States, Australia, Europe, Japan, China and other jurisdictions.
On Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust portfolio of treatments for people with serious illnesses all over the world. Editas Medicine aims to discover, develop, manufacture and commercialize precision, sustainable and transformative genomic medicines for a broad class of diseases. For the latest scientific information and presentations, please visit www.editasmedicine.com.
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate” “believe” “continue” “could” “estimate” ” ”expect” ”intend” ”can” ”plan” ”potential” ”predict” ”project” ”target” ,” ” should”, ”should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements due to a variety of factors, including: the uncertainties inherent in litigation, including patent interference proceedings; the uncertainties inherent in the initiation and completion of preclinical studies, clinical trials and clinical development of the Company’s product candidates; the availability and timing of results from preclinical studies and clinical trials; whether the interim results of a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations regarding regulatory approvals to conduct trials or to commercialize products and the availability of sufficient funding for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure needs. These and other risks are described in greater detail under the heading “Risk Factors” included in the company’s most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission, as updated. by the Company’s subsequent filings with the Securities and Exchange Commission, and in other documents that the Company may file with the Securities and Exchange Commission in the future. All forward-looking statements contained in this press release represent the views of the Company only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company expressly disclaims any obligation to update forward-looking statements.
CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 [email protected] Investors Ron Moldaver (617) 401-9052 [email protected]